Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

608
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
608
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577
Cancer Therapies02:49

Cancer Therapies

10.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.

International journal of cancer·2026
Same author

The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer.

Journal for immunotherapy of cancer·2026
Same author

Mastering Organoid Growth: A Complete Guide to Overcoming Methodological Challenges.

MedComm·2026
Same author

Optimized dose schedule of rucaparib and liposomal irinotecan/5-fluorouracil in metastatic gastrointestinal cancers: A phase 1 study.

Cancer·2025
Same author

Microsatellite instability: Advances in diagnosis.

Cancer·2025

Related Experiment Video

Updated: Mar 2, 2026

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
08:42

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)

Published on: June 27, 2025

2.5K

Immunotherapy for Colorectal Cancer.

Patrick M Boland1, Wen Wee Ma2

  • 1Roswell Park Cancer Institute, Department of Medicine, Elm and Carlton St, Buffalo, NY 14263, USA. Patrick.Boland@RoswellPark.org.

Cancers
|May 12, 2017
PubMed
Summary

Immunotherapy shows promise for mismatch repair deficient colorectal cancer. Research is expanding immunotherapy to earlier stages and combining it with other treatments to improve effectiveness in more patients.

Keywords:
anti-PD1colon cancerimmunotherapy

More Related Videos

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

4.0K
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.8K

Related Experiment Videos

Last Updated: Mar 2, 2026

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
08:42

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)

Published on: June 27, 2025

2.5K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

4.0K
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.8K

Area of Science:

  • Oncology
  • Immunology
  • Gastroenterology

Background:

  • Anti-PD1 drugs have shown success in a subset of metastatic colorectal cancer (CRC) patients with mismatch repair deficiency.
  • This success has spurred interest in immunotherapy for CRC, despite mismatch repair deficient tumors representing a small fraction of metastatic cases.

Purpose of the Study:

  • To review the current understanding of the immune and molecular characteristics of colorectal cancer.
  • To discuss ongoing clinical trials exploring novel combination strategies involving immune checkpoint inhibitors for CRC treatment.

Main Methods:

  • Literature review of contemporary research on the immune and molecular landscape in colorectal cancer.
  • Analysis of ongoing clinical trials investigating combination regimens with immune checkpoint inhibitors.

Main Results:

  • The abstract does not contain specific results but outlines the scope of the review and ongoing research.
  • Current research is focused on advancing immunotherapy to earlier stages (adjuvant and first-line metastatic) and enhancing sensitivity through combinatorial approaches.

Conclusions:

  • Immunotherapy holds potential for colorectal cancer, particularly when combined with other therapies.
  • Further research and clinical trials are crucial to broaden the application and efficacy of immunotherapy in various colorectal cancer settings.